

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

| | | | |
|---|---|--|--|
| 1. Name and Address of Reporting Person* <u>Ultragenyx Pharmaceutical Inc.</u> | 2. Date of Event Requiring Statement (Month/Day/Year) 06/19/2019 | 3. Issuer Name and Ticker or Trading Symbol <u>Arcturus Therapeutics Holdings Inc. [ARCT]</u> | |
| | | 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) | 5. If Amendment, Date of Original Filed (Month/Day/Year) |
| | | <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below) | <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person |
| (Last) (First) (Middle) 60 LEVERONI CT | | | |
| (Street) NOVATO CA 94949 | | | |
| (City) (State) (Zip) | | | |

Table I - Non-Derivative Securities Beneficially Owned

| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
|---------------------------------|---|--|---|
| Common Stock | 2,400,000 | D | |

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
|--|--|---------------------------|---|--|--|---|
| | Date Exercisable | Expiration Date | | | | |
| Option (Right to Buy) | 06/19/2019 | 06/18/2021 ⁽¹⁾ | Common Stock 600,000 ⁽²⁾ | 16 | D | |

Explanation of Responses:

- Under certain circumstances, the expiration date may be extended until June 18, 2023.
- The Reporting Person may only purchase that number of such shares that would result in the Reporting Person owning a number of shares of Common Stock equal to 19.99% of the then-issued and outstanding shares of Common Stock.

Remarks:

/s/ Karah Parschauer06/25/2019

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.